The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action

被引：19

作者：

Offord, SJ

Wong, DF

Nyberg, S

机构：

[1] Hoechst Marion Roussel Inc, Global Mkt, Bridgewater, NJ 08807 USA

[2] Johns Hopkins Med Inst, Dept Radiol, Div Nucl Med, Baltimore, MD 21205 USA

[3] Karolinska Inst, Dept Clin Neurosci, Psychiat Sect, Stockholm, Sweden

来源：

关键词：

D O I：

10.1002/j.1552-4604.1999.tb05933.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：17S / 24S

页数：8

共 26 条

[21] THE SELECTIVE 5-HT2A RECEPTOR ANTAGONIST, MDL-100,907, INCREASES DOPAMINE EFFLUX IN THE PREFRONTAL CORTEX OF THE RAT
SCHMIDT, CJ
FADAYEL, GM
[J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 273 (03) : 273 - 279
[22] SIGMUNDSON HK, 1994, CAN J PSYCHIAT, V39, pS70
[23] SORENSEN SM, 1993, J PHARMACOL EXP THER, V266, P684
[24] Tamminga CA, 1997, J CLIN PSYCHIAT, V58, P3
[25] TARSY D, 1983, CLIN NEUROPHARMACOL, V6, pS9
[26] Novartis' role in 21st century drug development
Vasella, D
[J]. NATURE BIOTECHNOLOGY, 1997, 15 (06) : 485 - 485